The drugmaker expects the regulator to remove Wegovy and Ozempic from its shortage list, blocking other companies from ...

CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.

A majority with overweight/obesity discontinue within a year, but the rate is higher among those without type 2 diabetes.

Among over 125,000 patients, 53.6% discontinued their GLP-1 receptor agonist by 1 year, and these rates were significantly ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

Led by an interest in GLP-1 weight loss drugs, more health care brands may advertise in the Super Bowl this year.

Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...

Recently, there has been a lot of buzz around GLP-1 weight loss injections. Talk of Ozempic or Wegovy has been hard to miss.

Discontinuation of GLP-1 receptor agonists in obesity is common, driven by weight regain and socioeconomic factors, impacting ...

Companies such as Teladoc and Omada Health have embraced GLP-1s while dangling the prospect of lowered costs to their ...

A randomized controlled trial demonstrated a significantly reduced incidence of type 2 diabetes among individuals with metabolic syndrome who received daily metformin with or without a Mediterranean ...

Novo’s newest GLP-1, CagriSema, is the first big test of Novo Nordisk’s future as the leader in the obesity treatment market.